The Biden administration’s recent proposal to seize control of certain drug patents as a means to lower prices could potentially face legal challenges. This move, considered a first by the U.S. government, specifically utilizes the less known “march-in rights”, and intends to license patents on drugs created with federal funding to alternative manufacturers.
A Bloomberg report suggests that stakeholders may likely challenge the administration’s decision to assert governmental control over intellectual property, thereby testing the breadth of its authority to do so.
The administration’s proposal was revealed when it floated a framework outlining how the government could assert control over certain drug patents judged as excessively priced. Administration officials indicate this to be a potentially groundbreaking application of the “march-in rights” under a 1980 law.
Once this plan is finalized, an anticipated legal contestation over the administration’s application of “march-in rights” is likely to stir up record-breaking debates in courts about the limits of governmental authority.
As the Biden administration maneuvers within legal frameworks to execute its healthcare plans, such tactics not only fuel the already present debate over the pricing of patented drugs, but also earliest legal battles over the extent of government power pertaining to intellectual property rights.
This unprecedented situation could provide a pivotal case study regarding the breadth of governmental power over intellectual property amid balancing economic interests, corporate rights, and public welfare in an increasingly globalizing world.